Drugs / 89Zr-DFO-N-Suc-C9scFv
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06645808 | Dec 2024 → Aug 2026 overdue | breast cancer, carcinoma of esophagus, chondrosarcoma, colon carcinoma +8 | Var2 Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-N-Suc-C9scFv | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06645808 ↗ |
| Modality | Protein / enzyme biologic | “89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.” NCT06645808 ↗ |
| Route | Intravenous | “single i.v. microdose (1 mg) administration of 89Zr-C9scFv 15 MBq” NCT06645808 ↗ |